...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of maternal-fetal & neonatal medicine >Evaluation of the effect of antenatal betamethasone on neonatal respiratory morbidities in late preterm deliveries (34-37 weeks)
【24h】

Evaluation of the effect of antenatal betamethasone on neonatal respiratory morbidities in late preterm deliveries (34-37 weeks)

机译：晚期早产送货上新生儿呼吸道病变对新生儿呼吸道生命的评价（34-37周）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background:Since late preterm neonates (34-36 weeks) are more at risk of respiratory morbidities, the present study was conducted to evaluate the effect of antenatal betamethasone on neonatal respiratory morbidities in women with late preterm delivery. Methods:This randomized clinical trial was performed on 240 women with single pregnancy that was at high risk of late preterm delivery (34-37 weeks). The patients were randomly assigned to either betamethasone (intramuscular injection of 12 mg of betamethasone in two doses with an interval of 24 hours) or the control group. The two groups were compared with each other in terms of respiratory morbidities, NICU admission and its cause and duration, hospitalization in the neonatal ward for more than 6 hours, and the duration of hospitalization. Results:Of all, 79 neonates (33%) had one or more respiratory morbidities. The observed morbidities in the betamethasone group were significantly less prevalent than those in the control group (19 neonates (16%) and 60 neonates (50%), respectively,p < .001). The most frequently observed respiratory morbidity was needed for oxygen for more than an hour (34 infants, 14%). The need for oxygen for more than an hour, the need for continuous positive airway pressure (CPAP), respiratory distress syndrome (RDS), and the need for surfactant were significantly less observed in betamethasone group than in the control group. A total of 43 neonates (18%) were admitted to NICU and then hospitalized in the neonatal ward; the number of admitted neonates were significantly lower in the betamethasone group than in the control group (11 neonates (9%) and 32 neonates (27%), respectively,p < .001). Moreover, 15 neonates (6%) were admitted to the neonatal ward and there were no significant differences between the betamethasone and control groups (10 neonates (8%) and 5 neonates (4%), respectively,p = .182). Totally, 58 neonates (24%) were hospitalized; the number of hospitalized neonates was significantly lower in the betamethasone group than in the control group (21 neonates (18%) and 37 neonates (31%), respectively,p = .016). Conclusion:The results of this study showed that the antenatal administration of betamethasone in late preterm delivery (34-37 weeks) can improve respiratory morbidities and decrease the frequency of NICU admission.
机译：背景：由于晚期早产新生儿（34-36周）更具呼吸状病病理风险，因此进行了本研究，以评估产前倍甲醇的作用对晚期早产的妇女新生儿呼吸道病态的影响。方法：该随机临床试验是对240名患有单身妊娠的妇女进行的，患有晚期早产的高风险（34-37周）。将患者随机分配给雌滴鼻体（肌内注射12毫克倍甲塞酮，两剂量为24小时）或对照组。两组在呼吸道病态，NICU入院及其原因和持续时间方面相互比较，新生儿病房住院超过6小时，以及住院期间的持续时间。结果：全部，79名新生儿（33％）有一个或多个呼吸道病态。观察到的倍甲岛组的病症比对照组（19个新生儿（16％）和60个新生儿（50％）分别为P <.001）。氧气需要最常观察到的呼吸发病率超过一个小时（34个婴儿，14％）。对氧气的需求超过一个小时，需要连续正气道压力（CPAP），呼吸窘迫综合征（RDS），并且在雌滴体组中观察到表面活性剂的需要显着较低，而不是对照组。总共43个新生儿（18％）被纳入Nicu，然后在新生儿病房住院;在β塞米松组中录取的新生儿的数量显着低于对照组（11个新生儿（9％）和32个新生儿（27％），P <.001）。此外，将15个新生儿（6％）纳入新生儿病房，并且苯甲塞酮和对照组之间没有显着差异（10个新生儿（8％）和5个新生儿（4％），P = .182）。完全，58名新生儿（24％）住院;在β塞米松组的住院新生儿的数量显着低于对照组（21例新生（18％）和37个新生酸盐（31％），P = .016）。结论：本研究的结果表明，雌滴体在晚期早产（34-37周）的产前施用可以改善呼吸状病病理和降低Nicu入院的频率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号